The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect

Eli Lilly (NYSE:LLY | LLY Price Prediction | LLY Price Prediction) is doing something unusual for a mega-cap: growing revenue at 48% year over year while shares trade only 7.8% higher year to date.

Mounjaro and Zepbound combined for $14.9 billion in Q2 revenue, and CEO David Ricks told investors “Lilly’s future, after 150 years, has never been brighter.” So here is the question I want to answer directly: can LLY shares reach $1,500 by the end of 2027?

Why LLY Shares Are Stuck Despite 48% Revenue Growth

The stock is stalling because expectations reset faster than fundamentals. Shares are down 9.95% over the past month even after climbing 3.34% in the last week.

Investors are digesting a 9% U.S. price decline (excluding rebate adjustments), heavy $2.78 billion in IPR&D charges from four Q2 acquisitions, and a 1-year gain of 52.08% that already priced in a lot of the incretin story. Beta sits at just 0.502, so this is a valuation-digestion story compounded by recent insider selling and Novo Nordisk competition anxiety.

Wall Street Sees 15% Upside. I Think They Are Underselling It

The Street’s consensus target is $1,325.39, implying roughly 15% upside from here. Coverage skews bullish: 6 strong buys, 18 buys, 4 holds, 1 sell, and 1 strong sell, with 80% bullish sentiment.

Our own model base case lands at $1,229.32 (a modest 6.63% upside) with the bull case at $1,383.40 and bear case at $1,051.57, at high confidence (0.9). Both look conservative to me.

With 19 upward EPS revisions for FY2027 in the last 30 days against just 4 downward, the analyst community is quietly repricing this business higher.

Path to $1,500 Per Share

Reaching $1,500 from today’s price of $1,152.93 would require a gain of 30.1%. With forward EPS of $38.25, a price of $1,500 implies a forward P/E of 39x. Our base case of $1,229.32 already implies 37x, meaning the bold target requires only 3x of additional multiple expansion.

That is a modest ask given the setup. The compression story is real: consensus FY2027 EPS sits at $47.32, up from $44.49 ninety days ago.

Catalysts are stacking: the August 28, 2026 FDA approval of Mounjaro for cardiovascular risk reduction, the September 18, 2026 approval of Inluriyo for ER+ breast cancer, and Ricks noting “really unprecedented efficacy with this triple acting GLP-1” ahead of the Q1 2027 retatrutide BLA submission.

The primary risk: any FDA setback on the retatrutide pathway could compress the multiple instead of expanding it.

Where LLY Trades Today vs Its Earnings Power

At $1,152.93 against forward EPS of $38.25, LLY currently trades at roughly 30x forward earnings. That is a reasonable multiple for a company growing revenue 47.67% year over year with 54.8% non-GAAP performance margins.

Shares sit near the 52-week high of $1,292.65, well off the 52-week low of $707.59. Ten-year returns of 1,587.78% tell you long-term compounders can absorb premium multiples when EPS growth keeps delivering.

Is $1,500 Realistic? My Verdict

Reaching $1,500 requires a 30.1% gain from here. I think it is realistic, provided three things happen: retatrutide clears the BLA pathway on schedule, Foundayo’s 36,000 prescriber base continues expanding, and FY2027 EPS estimates keep drifting toward the $54.94 high end.

What would derail it? A meaningful Novo Nordisk share-grab in obesity or a regulatory delay on retatrutide’s biologic classification. Returns at this level shouldn’t be expected every year, but we’ve outlined the blueprint for how Eli Lilly could reach $1,500 in 2027.

Contact [email protected] for any questions or corrections.